Search
Talbutal
go.drugbank.com/drugs/DB00306ApprovedIllicitTalbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalwell as an effect on increasing norepinephrine and dopamine neurotransmitters. … It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsOxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigational[L8627,L8630,L8633] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood … - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine].
Categories: P-glycoprotein inducers, P-glycoprotein substratesAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalAlectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsFlavin adenine dinucleotide
go.drugbank.com/drugs/DB03147Approved(Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency. … A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesClonazepam
go.drugbank.com/drugs/DB01068ApprovedIllicitInvestigationalNow available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. … A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 InhibitorsProducts: RIVOTRIL 1 MG/1 ML IV ÇÖZELTİ İÇEREN AMPUL, 5 ADETPariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801Approved[L64050,L64051] It is administered as a single, one-time intravenous infusion. … Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase
Tazemetostat
go.drugbank.com/drugs/DB12887ApprovedInvestigationalTazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. … [L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476]
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesTriamterene
go.drugbank.com/drugs/DB00384ApprovedTriamterene is a weak antagonist of folic acid, and a photosensitizing drug.[L6163] Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. … Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension.
Mixtures: TRIAMTEREN/HCT AL, TRIAMTEREN/HCT ALCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesClomipramine
go.drugbank.com/drugs/DB01242ApprovedInvestigationalVet approvedTertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. … See toxicity section below for a complete listing of side effects.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index